KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Assets (2018 - 2025)

Castle Biosciences' Non-Current Assets history spans 7 years, with the latest figure at $217.5 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 27.11% year-over-year to $217.5 million; the TTM value through Dec 2025 reached $771.1 million, up 15.0%, while the annual FY2025 figure was $217.5 million, 27.11% up from the prior year.
  • Non-Current Assets for Q4 2025 was $217.5 million at Castle Biosciences, up from $205.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $217.5 million in Q4 2025 and bottomed at $10.7 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $156.4 million (2023), against an average of $142.5 million.
  • The largest annual shift saw Non-Current Assets soared 1018.03% in 2021 before it fell 6.39% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $108.8 million in 2021, then skyrocketed by 42.46% to $155.0 million in 2022, then grew by 1.72% to $157.7 million in 2023, then increased by 8.48% to $171.1 million in 2024, then increased by 27.11% to $217.5 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Non-Current Assets are $217.5 million (Q4 2025), $205.2 million (Q3 2025), and $196.1 million (Q2 2025).